Tissue and Hematopoietic/Mesenchymal Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer
Phase NA Completed
9 enrolled 9 charts
Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma
Phase 3 Completed
482 enrolled
Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma
Phase 1 Terminated
6 enrolled
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
Phase 1/2 Completed
33 enrolled
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2 Completed
34 enrolled 11 charts
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
Phase 2 Terminated
3 enrolled 8 charts
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
Phase 1 Completed
33 enrolled
S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
Phase 3 Completed
432 enrolled 7 charts
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
Phase 1 Completed
16 enrolled
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer
Phase 2 Completed
19 enrolled
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase 1 Unknown
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
35 enrolled
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase 1 Completed
Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma
Phase 2 Completed
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
Phase 2 Terminated
58 enrolled
Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma
Phase 2 Completed
170 enrolled 23 charts
Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase 1 Completed
61 enrolled
Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma
Phase 1 Completed
136 enrolled